Delaware 2025-2026 Regular Session

Delaware Senate Bill SB120

Introduced
5/1/25  

Caption

An Act To Amend Titles 18, 29, And 31 Of The Delaware Code Relating To Health Insurance.

Impact

The impact of SB 120 on state laws includes a mandated change in the health insurance landscape, ensuring that policies issued or renewed after December 31, 2026 must include provisions for biomarker testing. This is a notable shift that updates the regulation to align with current medical practices and advances in health technology, thereby enhancing patient care options available in Delaware. Insurance plans will need to adapt their coverage structures to comply with this new requirement.

Summary

Senate Bill 120 aims to amend various titles of the Delaware Code related to health insurance, specifically requiring insurers to provide coverage for biomarker testing. This coverage is intended for tests that are supported by medical and scientific evidence for the diagnosis, treatment, and ongoing management of diseases. The inclusion of biomarker testing in insurance policies reflects a modern approach to healthcare, integrating genetic insights and personalized medicine practices into standard health insurance provisions.

Sentiment

The sentiment around SB 120 appears to be largely positive, particularly among healthcare providers and patient advocacy groups, who see the requirement for insurance coverage as a significant advancement in patient care and support. Opponents may raise concerns regarding the implications for insurance premiums and coverage limits, though these perspectives were not prominently featured in the discussions surrounding the bill.

Contention

Notable points of contention may arise regarding the definitions and standards surrounding what constitutes a 'biomarker' and the requirements for medical evidence to support the necessity of such tests. While the bill promotes coverage, there could be debates over whether all proposed tests meet the rigorous criteria set forth, including FDA approvals and clinical practice guidelines. Additionally, stakeholders may express concerns about ensuring equitable access to these testing options across different communities.

Companion Bills

No companion bills found.

Similar Bills

NJ S3098

Requires health insurers to provide coverage for biomarker precision medical testing.

NJ A4163

Requires health insurers to provide coverage for biomarker precision medical testing.

AZ HB2144

Health insurance coverage; biomarker testing

CA SB912

Biomarker testing.

CA SB496

Biomarker testing.

WV HB4753

Relating to providing health insurance coverage concerning biomarker testing

NM HB73

Biomarker Testing Insurance Requirements

MA H1074

Relative to cancer patient access to biomarker testing to provide appropriate therapy